Next Article in Journal
Development of a Novel Series of Anticancer and Antidiabetic: Spirothiazolidines Analogs
Next Article in Special Issue
Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide
Previous Article in Journal
Hemodynamic Effects on Particle Targeting in the Arterial Bifurcation for Different Magnet Positions
Previous Article in Special Issue
An Isoxazole Derivative SHU00238 Suppresses Colorectal Cancer Growth through miRNAs Regulation
Article Menu
Issue 13 (July-1) cover image

Export Article

Open AccessArticle

The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues

1
Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
2
Institute of Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
3
Core for Biomolecular Structure and Function, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
*
Authors to whom correspondence should be addressed.
Academic Editors: Yasuyoshi Miyata and George Kokotos
Molecules 2019, 24(13), 2510; https://doi.org/10.3390/molecules24132510
Received: 9 May 2019 / Revised: 25 June 2019 / Accepted: 4 July 2019 / Published: 9 July 2019
(This article belongs to the Special Issue Anti-Cancer Drug: Discovery, Development and Combination)
  |  
PDF [4862 KB, uploaded 11 July 2019]
  |  

Abstract

We recently reported that SF2312 ((1,5-dihydroxy-2-oxopyrrolidin-3-yl)phosphonic acid), a phosphonate antibiotic with a previously unknown mode of action, is a potent inhibitor of the glycolytic enzyme, Enolase. SF2312 can only be synthesized as a racemic-diastereomeric mixture. However, co-crystal structures with Enolase 2 (ENO2) have consistently shown that only the (3S,5S)-enantiomer binds to the active site. The acidity of the alpha proton at C-3, which deprotonates under mildly alkaline conditions, results in racemization; thus while the separation of four enantiomeric intermediates was achieved via chiral High Performance Liquid Chromatography (HPLC) of the fully protected intermediate, deprotection inevitably nullified enantiopurity. To prevent epimerization of the C-3, we designed and synthesized MethylSF2312, ((1,5-dihydroxy-3-methyl-2-oxopyrrolidin-3-yl)phosphonic acid), which contains a fully-substituted C-3 alpha carbon. As a racemic-diastereomeric mixture, MethylSF2312 is equipotent to SF2312 in enzymatic and cellular systems against Enolase. Chiral HPLC separation of a protected MethylSF2312 precursor resulted in the efficient separation of the four enantiomers. After deprotection and inevitable re-equilibration of the anomeric C-5, (3S)-MethylSF2312 was up to 2000-fold more potent than (3R)-MethylSF2312 in an isolated enzymatic assay. This observation strongly correlates with biological activity in both human cancer cells and bacteria for the 3S enantiomer of SF2312. Novel X-ray structures of human ENO2 with chiral and racemic MethylSF2312 show that only (3S,5S)-enantiomer occupies the active site. Enolase inhibition is thus a direct result of binding by the (3S,5S)-enantiomer of MethylSF2312. Concurrent with these results for MethylSF2312, we contend that the (3S,5S)-SF2312 is the single active enantiomer of inhibitor SF2312. View Full-Text
Keywords: glycolysis; enolase; chiral; phosphonate; hydroxamate; E. coli; enzyme inhibitor; enzyme structure; natural product; X-ray crystallography glycolysis; enolase; chiral; phosphonate; hydroxamate; E. coli; enzyme inhibitor; enzyme structure; natural product; X-ray crystallography
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Pisaneschi, F.; Lin, Y.-H.; Leonard, P.G.; Satani, N.; Yan, V.C.; Hammoudi, N.; Raghavan, S.; Link, T.M.; K. Georgiou, D.; Czako, B.; Muller, F.L. The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues. Molecules 2019, 24, 2510.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top